Vaccination is a critical tool for controlling infectious diseases, with its use to protect against COVID-19 being a prime example. Where a disease is highly transmissible, even a small proportion of unvaccinated individuals can have substantial implications for disease burdens and compromise efforts for control. As socio-demographic factors such as deprivation and ethnicity have been shown to influence uptake rates, identifying how vaccine uptake varies with socio-demographic indicators is a critical step for reducing vaccine hesitancy and issues of access, and identifying plausible future uptake patterns. Here, we analyse the numbers of COVID-19 vaccinations subdivided by age, gender, date, dose and geographical location. We use publicly available socio-demographic data, and use random forest models to capture patterns of uptake at high spatial resolution, with systematic variation restricted to fine spatial scale (~1km in urban areas). We show that uptake of first vaccine booster doses in Scotland can be used to predict with high precision the distribution of second booster doses across deprivation deciles, age and gender despite the substantially lower uptake of second boosters compared to first. This analysis shows that while age and gender have the greatest impact on the model fit, there is a substantial influence of several deprivation factors and the proportion of BAME residents. The high correlation amongst these factors also suggests that, should vaccine uptake decrease, the impact of deprivation is likely to increase, furthering the disproportionate impact of COVID-19 on individuals living in highly deprived areas. As our analysis is based solely on publicly available socio-demographic data and readily recorded vaccination uptake figures, it would be easily adaptable to analysing vaccination uptake data from countries where data recording is similar, and for aiding vaccination campaigns against other infectious diseases.
Aim. To assess whether exposure to proton pump inhibitors (PPIs) shortly preceding COVID-19 diagnosis affected the risk of subsequent hospitalizations and mortality. Methods. This population-based study embraced first COVID-19 episodes in adults diagnosed up to August 15 2021 in Croatia. Patients were classified based on exposure to PPIs and burden of PPI-requiring morbidities as “non-users” (no issued prescriptions, no recorded treatment-requiring conditions between January 1 2019 and COVID-19 diagnosis), “possible users” (no issued prescriptions, but morbidities present; self-medication possible) and “users” (at least one prescription within 3 months prior to the COVID-19 diagnosis; morbidities present ). Subsets were mutually exactly matched for pre-COVID-19 characteristics. The contrast between “users” and “possible users” informed about the effect of PPIs that is separate of the effect of PPI-requiring conditions. Results. Among 433609 patients, “users” and “possible users” were matched 41195 (of 55098) to 17334 (of 18170) in the primary and 33272 to 16434 in the sensitivity analysis. There was no relevant difference between them regarding mortality [primary: RR=0.93 (95%CI 0.85-1.02; RD= -0.34% (-0.73, 0.03); sensitivity: RR=0.88 (0.78-0.98); RD=-0.45% (-0.80, -0.11)] or hospitalizations [primary: RR=1.04 (0.97-1.13); RD=0.29% (-0.16, 0.73); sensitivity: RR=1.05 (0.97-1.15); RD=0.32% (-0.12, 0.75)]. The risks of both were slightly higher in “possible users” or “users” than in “non-users” (absolutely by ≈0.4%-1.6%) indicating the effect of PPI-requiring morbidities. Conclusion. Pre-morbid exposure to PPIs does not affect the risk of death or hospitalization in adult COVID-19 patients, but PPI-requiring morbidities seemingly slightly increase the risk of both.
Rationale: Exhaled breath condensate (EBC) promises a valuable, non-invasive, and easy to obtain clinical sample. However, it is not currently used diagnostically due to poor reproducibility, sample contamination, and sample loss. Objective: We evaluated whether a new, hand-held EBC collector (PBM-HALE) that separates inertially impacted large droplets (LD) before condensing fine aerosols (FA) in distinct, self-sealing containers, overcomes current limitations. Methods: Sampling consistency was determined in healthy volunteers by microbial culture, 16S phylogenetics, spectrophotometry, RT-PCR, and HILIC-MS. Capture of aerosolised polystyrene beads, liposomes, virus-like particles, or pseudotyped virus was analysed by nanoparticle tracking analysis, reporter expression assays, and flow cytometry. Acute symptomatic COVID-19 case tidal FA EBC viral load was quantified by RT-qPCR. Exhaled particles were counted by laser light scattering. Measurements and Main Results: Salivary amylase-free FA EBC capture was linear (R2=0.9992; 0.25-30 min) yielding RNA (6.03 ug/mL) containing eukaryotic 18S rRNA (RT-qPCR; p<0.001) but not human GAPDH, RNase P, or beta actin mRNA;141 non-volatile metabolites included eukaryotic cell membrane components, and cuscohygrine 3 days after cocaine abuse. Culturable aerobe viability was condensation temperature-dependent. Breath fraction-specific microbiota were stable, identifying Streptococcus enrichment in a mild dry cough case. Nebulized pseudotyped virus infectivity loss <67% depended on condensation temperature, and particle charge-driven aggregation. SARS-CoV-2 RNA genomes were detected only by forced expiration FA EBC capture, in 100% of acute COVID-19 patients. Conclusions: High purity, distal airway FA EBC can reproducibly and robustly inform contamination-free infectious agent emission sources, and be quantitatively assayed for multiple host, microbial, and lifestyle biomarker classes.
Abstract Since coronavirus disease 2019 (COVID-19) has continued to spread globally, many countries have started vaccinations at the end of December 2020. This research examines the relationship between COVID-19 vaccine distribution and two macro-socioeconomics measures, including human development index and gross domestic product, among 25 countries for two points in time, including February and August 2021. The COVID-19 dataset is a collection of the COVID-19 data maintained by Our World in Data. It is a daily updated dataset and includes confirmed cases, vaccinations, deaths, and testing data. Ordinary Least Squares was applied to examine how macro-socioeconomic measures predict the distribution of the COVID-19 vaccine over time. Results: The results indicate that a higher gross domestic product per capita is positively associated with higher COVID-19 vaccine distribution, and this relationship becomes more robust over time. However, some countries may have more successful vaccine distribution results regardless of their gross domestic product. In addition, the result shows human development index does not have a significant relationship with vaccine distribution. Conclusion: Economic measures may be counted as a more vital indicator for vaccine distribution as they have a more direct relationship distribution with health infrastructure than social measures such as human development index.
Booster Study of COVID-19 Protein Subunit Recombinant Vaccine - Condition: COVID-19
Interventions: Biological: SARS-CoV-2 subunit protein recombinant vaccine; Biological: Active Comparator
Sponsors: PT Bio Farma; Faculty of Medicine Universitas Padjadjaran; Faculty of Medicine Universitas Udayana
Recruiting
A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine SCTV01E-1 in Population Aged Above 18 Years - Conditions: COVID-19; SARS-CoV-2 Infection
Interventions: Biological: SCTV01E-1 on D0; Biological: SCTV01E-1 on D28; Biological: SCTV01E-1 on D150; Biological: SCTV01E on D0; Biological: SCTV01E on D28; Biological: SCTV01E on D150; Biological: SCTV01E-1 on D120; Biological: SCTV01E on D120
Sponsor: Sinocelltech Ltd.
Not yet recruiting
A Novel Parameter LIT/N That Predicts Survival in COVID-19 ICU Patients - Condition: COVID-19 Pneumonia
Intervention: Diagnostic Test: the LIT test
Sponsors: Gazi University; Oxford MediStress
Completed
Efficacy and Safety of ES16001 in Patients With COVID-19 - Condition: COVID-19
Interventions: Drug: ES16001 40 mg; Drug: ES16001 80 mg; Drug: ES16001 160 mg; Drug: Placebo
Sponsor: Genencell Co. Ltd.
Recruiting
Phase 2a Trial to Evaluate Safety and Immunogenicity of COVID-19 Vaccine Strategies in HIV-infected/Uninfected Adults. - Condition: COVID-19
Intervention: Drug: Ad26.COV2.S (VAC31518, JNJ-78436735) Vaccine, SARS-CoV-2 rS (CovovaxTM), BNT162b2 (Pfizer)
Sponsors: The Aurum Institute NPC; Coalition for Epidemic Preparedness Innovations
Recruiting
COVID Protection After Transplant - Sanofi GSK (CPAT-SG) Study - Conditions: COVID-19; Kidney Transplant
Intervention: Biological: Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); PPD; Johns Hopkins University; Sanofi Pasteur, a Sanofi Company
Not yet recruiting
Safety and Immunogenicity of COVID-19 Vaccine, AdCLD-CoV19-1 - Conditions: COVID-19; Vaccines
Intervention: Biological: AdCLD-CoV19-1
Sponsors: International Vaccine Institute; Cellid Co., Ltd.
Not yet recruiting
Smartphone Intervention for Overdose and COVID-19 - Conditions: Substance Use Disorders; Overdose; COVID-19
Intervention: Device: iThrive WI Intervention
Sponsors: University of Wisconsin, Madison; National Institute on Drug Abuse (NIDA)
Not yet recruiting
A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine - Conditions: COVID-19; Influenza
Interventions: Drug: CIC Vaccine; Drug: qNIV Vaccine; Drug: SARS-CoV-2 rS Vaccine; Drug: Influenza Vaccine
Sponsor: Novavax
Not yet recruiting
Study to Assess Efficacy and Safety of Treamid for Patients With Reduced Exercise Tolerance After COVID-19 - Conditions: SARS-CoV-2 Infection; Lung Fibrosis
Interventions: Drug: Treamid; Drug: Treamid twice a day; Drug: Treamid once a day; Drug: Placebo
Sponsor: PHARMENTERPRISES LLC
Not yet recruiting
Self-proning and Repositioning in COVID-19 Outpatients at Risk of Complicated Illness - Conditions: COVID-19; COVID-19 Pneumonia; Proning; Hospitalization; Death; Outpatient; Complication
Intervention: Other: Self-proning
Sponsors: Unity Health Toronto; Applied Health Research Centre
Recruiting
Effects of Immulina TM Supplements With PASC Patients - Condition: Post Acute COVID-19 Syndrome
Interventions: Dietary Supplement: Immulina TM; Dietary Supplement: Placebo
Sponsors: University of Mississippi Medical Center; National Institute of General Medical Sciences (NIGMS)
Not yet recruiting
Evaluation of Clinical Performance and Usability of iStatis COVID-19 Ag Rapid Test at POC - Conditions: COVID-19 Virus Infection; COVID-19; Coronavirus Disease-19; COVID-19 Pandemic; SARS-CoV-2 Infection
Interventions: Diagnostic Test: iStatis COVID-19 Ag Rapid Test; Diagnostic Test: “COVID-19 RT-PCR Test EUA Number: EUA200011, Company: Laboratory Corporation of America (”Labcorp")
Sponsor: bioLytical Laboratories
Completed
Resilience Intervention for Health Professionals COVID-19 - Condition: Mental Health Wellness 1
Intervention: Other: Mindfulness-based Intervention
Sponsor: Universidad de Monterrey
Completed
Addressing Post-COVID-19 Musculoskeletal Symptoms - Conditions: Telemedicine; Musculoskeletal Disease; SARS-CoV-2; Pain; COVID-19; Exercise
Interventions: Other: Multicomponent exercise program; Other: Tele-health primary care rehabilitation program
Sponsor: Universidad Europea de Madrid
Not yet recruiting
Beyond the vaccines: a glance at the small molecule and peptide-based anti-COVID19 arsenal - Unprecedented efforts of the researchers have been witnessed in the recent past towards the development of vaccine platforms for the control of the COVID-19 pandemic. Albeit, vaccination stands as a practical strategy to prevent SARS-CoV-2 infection, supplementing the anti-COVID19 arsenal with therapeutic options such as small molecules/peptides and antibodies is being conceived as a prudent strategy to tackle the emerging SARS-CoV-2 variants. Noteworthy to mention that collective efforts from…
Targeting spike protein-induced TLR/NET axis by COVID-19 therapeutic NRICM102 ameliorates pulmonary embolism and fibrosis - The global COVID-19 pandemic remains a critical public health threat, as existing vaccines and drugs appear insufficient to halt the rapid transmission. During an outbreak from May to August 2021 in Taiwan, patients with severe COVID-19 were administered NRICM102, which was a traditional Chinese medicine (TCM) formula developed based on its predecessor NRICM101 approved for treating mild cases. This study aimed to explore the mechanism of NRICM102 in ameliorating severe COVID-19-related embolic…
Computational investigation of potent inhibitors against SARS-CoV-2 2’-O-methyltransferase (nsp16): Structure-based pharmacophore modeling, molecular docking, molecular dynamics simulations and binding free energy calculations - The Coronavirus Disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, has created unprecedented public health and economic crises around the world. SARS-CoV-2 2’-O-methyltransferase (nsp16) adds a “cap” to viral RNA to maintain the stability of viral RNA, and inhibition of nsp16 activity may reduce viral proliferation, making this protein an attractive drug target. Here, we report the identification of several small molecule inhibitors of…
A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19 - Baricitinib is an oral, selective inhibitor of Janus kinase (JAK)1/JAK2 that transiently and reversibly inhibits many proinflammatory cytokines. This mechanism is a key mediator in a number of chronic inflammatory diseases; accordingly, baricitinib has been studied and approved for the treatment of several rheumatological and dermatological disorders, as well as COVID-19. This narrative review summarises and discusses the safety profile of baricitinib across these diseases, with special focus on…
Screening, molecular simulation and in silico kinetics of virtually designed Covid main protease inhibitors - Coronavirus (covid-19) infection is considered to deadliest ever pandemic experienced by the human being. It has very badly affected the socio-economic health of human and stuck the scientific community to think and rethink about its complete eradication. But due to no effective treatment or unavailability of vaccine the health professional could not show any significant improvement to control the pandemic. The situation needs newer molecule, vaccine or effective treatment to control covid-19…
ZnO-chlorogenic acid nanostructured complex inhibits Covid-19 pathogenesis and increases hydroxychloroquine efficacy - The study purpose was to compare the anti- the novel coronavirus disease 2019 (COVID-19) property of chlorogenic acid (CGA) and Zinc oxide nanoparticles (ZnO-NP) with the new valid synthesized complex of ZnO /CGA-NPs. Methods The facile mixing method was utilized to prepare ZnO/CGA-NPs. The in vitro effect of different ZnO/CGA-NPs concentrations on papain-like protease (PL^(pro)) and spike protein- receptor-binding domain (RBD) was measured by ELISA technique. The compounds effects on SARS-CoV2…
Emodin from Aloe inhibits Swine acute diarrhea syndrome coronavirus in cell culture - Swine acute diarrhea syndrome coronavirus (SADS-CoV) is an emerging swine enteropathogenic coronavirus that causes severe diarrhea in neonatal piglets, leading to serious economic losses to the pig industries. At present, there are no effective control measures for SADS, making an urgent need to exploit effective antiviral therapies. Here, we confirmed that Aloe extract (Ae) can strongly inhibit SADS-CoV in Vero and IPI-FX cells in vitro. Furthermore, we detected that Emodin from Ae had…
Folic acid restricts SARS-CoV-2 invasion by methylating ACE2 - The current COVID-19 pandemic is motivating us to elucidate the molecular mechanism of SARS-CoV-2 invasion and find methods for decreasing its transmissibility. We found that SARS-CoV-2 could increase the protein level of ACE2 in mice. Folic acid and 5-10-methylenetetrahydrofolate reductase (MTHFR) could promote the methylation of the ACE2 promoter and inhibit ACE2 expression. Folic acid treatment decreased the binding ability of Spike protein, pseudovirus and inactivated authentic SARS-CoV-2 to…
SARS-CoV-2 Infection-Associated Aortic Thrombosis Treated with Oral Factor Xa Inhibition - Coronavirus disease 2019 (COVID-19) is an acute complex systemic disorder caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).While SARS-CoV-2 is known to cause significant pulmonary disease, various extrapulmonary manifestations of COVID-19 have also been reported. Growing evidence suggests that COVID-19 is associated with coagulopathy leading to micro and macrovascular complications. Although in patients with COVID-19, venous thromboembolic events are more frequent,…
Investigation into the in vivo mechanism of diosmetin in patients with breast cancer and COVID-19 using bioinformatics - Patients with breast cancer are prone to SARS-CoV-2 infection [the causative virus of coronavirus disease (COVID-19)] due to their lack of immunity. In the current study, we examined the mechanism of action of Diosmetin, a flavonoid with anti-inflammatory properties, in patients with BRCA infected with SARS-CoV-2.We used bioinformatics technology to analyze the binding ability, biological function, and other biological characteristics of Diosmetin in vivo and examine the core target and…
Ruxolitinib inhibits cytokine production by human lung macrophages without impairing phagocytic ability - Background: The Janus kinase (JAK) 1/2 inhibitor ruxolitinib has been approved in an indication of myelofibrosis and is a candidate for the treatment of a number of inflammatory or autoimmune diseases. We assessed the effects of ruxolitinib on lipopolysaccharide (LPS)- and poly (I:C)-induced cytokine production by human lung macrophages (LMs) and on the LMs’ phagocytic activity. Methods: Human LMs were isolated from patients operated on for lung carcinoma. The LMs were cultured with ruxolitinib…
Nutraceutical prospects of Houttuynia cordata against the infectious viruses - The novel enveloped β-coronavirus SARS-CoV-2 (COVID-19) has offered a surprising health challenge all over the world. It develops severe pneumonia leading to acute respiratory distress syndrome (ARDS). Like SARS-COV-2, other encapsulated viruses like HIV, HSV, and influenza have also offered a similar challenge in the past. In this regard, many antiviral drugs are being explored with varying degrees of success to combat the associated pathological conditions. Therefore, upon scientific…
A DNA-based non-infectious replicon system to study SARS-CoV-2 RNA synthesis - The COVID-19 pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has seriously affected public health around the world. In-depth studies on the pathogenic mechanisms of SARS-CoV-2 is urgently necessary for pandemic prevention. However, most laboratory studies on SARS-CoV-2 have to be carried out in BSL-3 laboratories, greatly restricting the progress of relevant experiments. In this study, we used a bacterial artificial chromosome (BAC) method to assemble a…
The mechanism of metal-based antibacterial materials and the progress of food packaging applications: A review - Food packages have been detected carrying novel coronavirus in multi-locations since the outbreak of COVID-19, causing major concern in the field of food safety. Metal-based supported materials are widely used for sterilization due to their excellent antibacterial properties as well as low biological resistance. As the principal part of antibacterial materials, the active component, commonly referred to Ag, Cu, Zn, etc., plays the main role in inhibiting and killing pathogenic microorganisms by…
Heterologous Prime-boost of SARS-CoV-2 Inactivated Vaccine and mRNA BNT162b2 among Healthy Thai Adolescents - CONCLUSIONS: Heterologous prime-boost vaccination with CoronaVac followed by BNT162b2 induced high neutralizing titer against SARS-CoV-2 Delta strain. After 5-month interval, booster with BNT162b2 induced high neutralizing titer against Omicron strain.Thai Clinical Trials Registry (thaiclinicaltrials.org): TCTR20210923012.